<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02913729</url>
  </required_header>
  <id_info>
    <org_study_id>M15PAP</org_study_id>
    <secondary_id>NL53862.031.15</secondary_id>
    <nct_id>NCT02913729</nct_id>
  </id_info>
  <brief_title>Pre- Versus Postoperative Accelerated Partial Breast Irradiation</brief_title>
  <acronym>PAPBI-2</acronym>
  <official_title>Pre- Versus Postoperative Accelerated Partial Breast Irradiation in Early Stage Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most of the local recurrences (LR) found after breast-conserving therapy are within or close&#xD;
      to the tumor bed. This pattern of recurrence was confirmed by studies of breast conserving&#xD;
      surgery without adjuvant irradiation and by the update of the NSABP B-06 trial. In the EORTC&#xD;
      boost trial, however, 29% of all LR were found outside the area of the original tumor. Still,&#xD;
      a recent review of Breast Conserving Therapy (BCT) trials showed that the site of local&#xD;
      recurrences after BCT was mostly in the tumor bed, with less than 10% of LR elsewhere in the&#xD;
      breast. This led to the concept of partial breast irradiation. With accelerated partial&#xD;
      breast irradiation (APBI), a limited volume of breast tissue is irradiated, allowing for a&#xD;
      higher dose per fraction compared to whole breast irradiation (WBI), which is favorable&#xD;
      considering the low alpha/beta ratio, and thus higher sensitivity to high dose per fraction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will undergo a partial accelerated breast irradiation pre-or postoperative of 5 x&#xD;
      5.2 Gy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2016</start_date>
  <completion_date type="Anticipated">October 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cosmetic outcome</measure>
    <time_frame>3 years</time_frame>
    <description>cosmetic effect will be measured by comparing the treated breast with the contralateral breast. Cosmetic effect will be scored in three different ways: by digital photographs, patient's questionnaires and specialist's questionnaires. These data will result in an overall cosmetic outcome, scored as excellent, good, fair or poor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tumor response</measure>
    <time_frame>6 weeks</time_frame>
    <description>pathologic response will be measured in the removed tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative complications</measure>
    <time_frame>6 weeks</time_frame>
    <description>The expected acute surgical complication rate is approximately 16%. A stopping rule is set at 15% for complications that require hospitalization (including intravenous antibiotics) and re-surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Cancer of the Breast</condition>
  <condition>Neoplasms, Breast</condition>
  <arm_group>
    <arm_group_label>radiotherapy in arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pre-operative accelerated partial breast irradiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiotherapy in arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>post-operative accelerated partial breast irradiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>partial breast irradiation</intervention_name>
    <description>irradiation</description>
    <arm_group_label>radiotherapy in arm 1</arm_group_label>
    <arm_group_label>radiotherapy in arm 2</arm_group_label>
    <other_name>partial breast radiotherapy</other_name>
    <other_name>accelerated breast irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients ≥ 51 years&#xD;
&#xD;
          -  clinical stage tumor-1-2 (≤ 3 cm)&#xD;
&#xD;
          -  cN0&#xD;
&#xD;
          -  Grade I or grade II (biopsy)&#xD;
&#xD;
          -  Histologically proven invasive ductal adenocarcinoma&#xD;
&#xD;
          -  Unifocal lesions on mammogram and MRI (small satellite lesions adjacent to the tumor&#xD;
             are accepted as long as it is suitable for local excision to be determined by the&#xD;
             participating centre)&#xD;
&#xD;
          -  World Health Organization performance status ≤ 2&#xD;
&#xD;
          -  Life expectancy ≥ 5 years&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Distant metastases&#xD;
&#xD;
          -  Lobular invasive carcinomas&#xD;
&#xD;
          -  Pure Ductal Carcinoma in situ (DCIS) without invasive tumor&#xD;
&#xD;
          -  Grade III in biopsy&#xD;
&#xD;
          -  Triple negative tumors&#xD;
&#xD;
          -  HER2neu positive tumors&#xD;
&#xD;
          -  Lymphvascular invasion in biopsy&#xD;
&#xD;
          -  TNM pathologic stage N1-3&#xD;
&#xD;
          -  pN+ (micro- or macrometastases)&#xD;
&#xD;
          -  Multicentric / multifocal disease on mammogram or MRI&#xD;
&#xD;
          -  Diffuse calcifications on mammogram (Birads 3, 4 or 5)&#xD;
&#xD;
          -  Prior treatment for the protocol tumor (no surgery, no neoadjuvant chemotherapy or&#xD;
             neoadjuvant hormonal therapy, no previous radiotherapy)&#xD;
&#xD;
          -  Previous contralateral breast cancer&#xD;
&#xD;
          -  Other neoplasms in the last 5 years with the exception of:&#xD;
&#xD;
          -  Basal cell carcinoma of the skin&#xD;
&#xD;
          -  Adequately treated carcinoma in situ of the cervix&#xD;
&#xD;
          -  Planned oncoplastic resection with tissue displacement&#xD;
&#xD;
          -  No social security affiliation/health insurance&#xD;
&#xD;
          -  Participation in another clinical trial that interferes with the locoregional&#xD;
             treatment of this protocol&#xD;
&#xD;
          -  It is expected that dosimetric constraints cannot be met, ie, lung/heart constraints&#xD;
             or if the ratio PTV/ipsilateral breast &gt;30%&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>51 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Astrid Scholten, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Astrid Scholten, MD, PhD</last_name>
    <phone>+31 20 512 9111</phone>
    <email>a.scholten@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicola Russell, MD, PhD</last_name>
    <phone>+31 20 512 9111</phone>
    <email>n.russell@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paulien G Westhoff, MD, PhD</last_name>
      <phone>+31616423821</phone>
      <email>Paulien.Westhoff@radboudumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid Scholten, MD, PhD</last_name>
      <phone>+31 20 512 9111</phone>
      <email>a.scholten@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>Nicola Russell, MD, PhD</last_name>
      <phone>+31 20 512 9111</phone>
      <email>n.russell@nki.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht (UMCU)</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Femke Stam-van der Leij, MD/PhD</last_name>
      <email>F.vanderleij-2@umcutrecht.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Champilamaud Cancer Center</name>
      <address>
        <city>Lisboa</city>
        <zip>1400-038</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Passanzini, MD, PhD</last_name>
      <phone>+351 210 480 048</phone>
      <email>marco.possanzini@fundacaochampalimaud.pt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University General Hospital Valencia-Erasa</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amparo Gonzalez Sanchis, MD, PhD</last_name>
      <phone>+34 96 346 88 53</phone>
      <email>agonzales@erasa.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad WJ, Oei SB, Wárlám-Rodenhuis CC, Pierart M, Collette L. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007 Aug 1;25(22):3259-65. Epub 2007 Jun 18.</citation>
    <PMID>17577015</PMID>
  </reference>
  <reference>
    <citation>Cajucom CC, Tsangaris TN, Nemoto T, Driscoll D, Penetrante RB, Holyoke ED. Results of salvage mastectomy for local recurrence after breast-conserving surgery without radiation therapy. Cancer. 1993 Mar 1;71(5):1774-9.</citation>
    <PMID>8448741</PMID>
  </reference>
  <reference>
    <citation>Elkhuizen PH, van de Vijver MJ, Hermans J, Zonderland HM, van de Velde CJ, Leer JW. Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival. Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):859-67.</citation>
    <PMID>9531371</PMID>
  </reference>
  <reference>
    <citation>Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002 Oct 17;347(16):1233-41.</citation>
    <PMID>12393820</PMID>
  </reference>
  <reference>
    <citation>Osborne MP, Borgen PI, Wong GY, Rosen PP, McCormick B. Salvage mastectomy for local and regional recurrence after breast-conserving operation and radiation therapy. Surg Gynecol Obstet. 1992 Mar;174(3):189-94.</citation>
    <PMID>1542833</PMID>
  </reference>
  <reference>
    <citation>Sanders ME, Scroggins T, Ampil FL, Li BD. Accelerated partial breast irradiation in early-stage breast cancer. J Clin Oncol. 2007 Mar 10;25(8):996-1002. Review. Erratum in: J Clin Oncol. 2007 Aug 10;25(23):3561.</citation>
    <PMID>17350949</PMID>
  </reference>
  <reference>
    <citation>Veronesi U, Volterrani F, Luini A, Saccozzi R, Del Vecchio M, Zucali R, Galimberti V, Rasponi A, Di Re E, Squicciarini P, et al. Quadrantectomy versus lumpectomy for small size breast cancer. Eur J Cancer. 1990;26(6):671-3.</citation>
    <PMID>2144153</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 4, 2016</study_first_submitted>
  <study_first_submitted_qc>September 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2016</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>data from this clinical trial will be shared with the previous PAPBI clinical trial</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

